Aligos Therapeutics Gross Profit

Aligos Therapeutics (ALGS) currently reports a gross profit of $31M as of June 2026. That compares with $980K in the prior-year period — up 3030.3% year over year. That is below the Healthcare sector average of $65B. Use the charts on this page to explore Aligos Therapeutics's gross profit history and peer comparisons.

Aligos Therapeutics's gross profit increased from $980K to $31M — a 3030.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aligos Therapeutics's gross profit of $31M is lower than the Healthcare sector average of $65B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Aligos Therapeutics reported $31M in gross profit as of June 2026. That compares with $980K in the prior-year period — up 3030.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $31M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $65B. From there, open related valuation or income-statement pages for Aligos Therapeutics, and consider following ALGS for alerts when major investors trade the stock.